<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="70478">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01879241</url>
  </required_header>
  <id_info>
    <org_study_id>RAS-ALS</org_study_id>
    <secondary_id>2011-004482-32</secondary_id>
    <nct_id>NCT01879241</nct_id>
  </id_info>
  <brief_title>Study of Rasagiline in Patients With Amyotrophic Lateral Sclerosis</brief_title>
  <official_title>Efficacy, Safety and Tolerability Study of 1 mg Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS) Receiving Standard Therapy (Riluzole) - An AMG Trial With a Market Authorized Substance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Ulm</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Ulm</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the trial is to investigate the survival time (the time from
      randomization until death or end of the trial) compared between control group and
      experimental group.

      This is a prospective, multicenter, randomized, stratified, parallel-group, double-blind
      trial comparing placebo with 1 mg/d rasagiline as add-on therapy to 100 mg riluzole in
      amyotrophic lateral sclerosis (ALS) in 250 enrolled patients. For entry, the El Escorial
      Criteria for the diagnosis of ALS will be used. The patients have to be stable on riluzole
      at least 4 weeks prior to randomization.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">August 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Survival in ALS-Patients with Rasagiline compared to placebo</measure>
    <time_frame>18 Months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of total score of ALS Functional Rating Scale - Revised (ALSFRS-R)</measure>
    <time_frame>18 Months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of individual Quality of Life (SEIQoL, Schedule for the Evaluation of Individual Quality of Life</measure>
    <time_frame>18 Months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of slow vital capacity</measure>
    <time_frame>18 Months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Rasagiline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rasagiline
1 mg/day; 18 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>once daily, 18 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rasagiline</intervention_name>
    <arm_group_label>Rasagiline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>a sugar pill manufactured to mimic Rasagiline 1 mg tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Possible, probable (clinically or laboratory) or definite ALS according to the
             revised version of the El Escorial World Federation of Neurology criteria

          -  Disease duration more than 6 months and less than 3 years (inclusive). Disease onset
             defined as date of first muscle weakness, excluding fasciculations and cramps

          -  Vital capacity more than 50% of normal (slow vital capacity; best of three
             measurements)

          -  Age: ≥ 18 years

          -  Continuously treated with 100 mg riluzole for at least four weeks

          -  Capable of thoroughly understanding all information given and giving full informed
             consent according to GCP

          -  Women of childbearing age must be non-lactating and surgically sterile or using a
             highly effective method of birth control and have a negative pregnancy test.
             Acceptable methods of birth control with a low failure rate i.e. less than 1% per
             year) when used consistently and correct are such as implants, injectables, combined
             oral contraceptives, hormonal intrauterine devices (IUDs), or double-barrier methods
             (condom or diaphragm with spermicidal agent or IUD), sexual abstinence or
             vasectomized partner

        Exclusion Criteria:

          -  Previous participation in another clinical study within the preceding 12 weeks

          -  Tracheostomy or assisted ventilation of any type during the preceding three months

          -  Gastrostomy

          -  Any medical condition known to have an association with motor neuron dysfunction
             which might confound or obscure the diagnosis of ALS

          -  Presence of any concomitant life-threatening disease or impairment likely to
             interfere with functional assessment

          -  Patients on sympathomimetic agents. This includes pseudoephedrine, phenylephrine,
             phenylpropanolamine, and ephedrine.

          -  Patients on analgesics with serotoninergic properties such as meperidine, tramadol,
             methadone and propoxyphene.

          -  Patients on serotonin reuptake inhibitors (SSRIs). This includes fluoxetine or
             fluvoxamine.

          -  Patients on dextromethorphan, St. John's wort, cyclobenzaprine or other MAO
             inhibitors (selective or non-selective)

          -  Patients taking Antidepressants

          -  Confirmed hepatic insufficiency or abnormal liver function (ASAT and/or ALAT greater
             than 3 times the upper limit of the normal range)

          -  Renal insufficiency (serum creatinine more than 2.26 mg/dL)

          -  Evidence of major psychiatric disorder or clinically evident dementia precluding
             evaluation of symptoms

          -  Known hypersensitivity to any component of the study drug

          -  Liable to be not cooperative or comply with the trial requirements (as assessed by
             the investigator), or unable to be reached in the case of emergency

          -  Female with childbearing potential, if no adequate contraceptive measures are used

          -  Pregnancy or breast-feeding females
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Albert C. Ludolph, MD, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neurology, University of Ulm</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Albert C Ludolph, MD, Prof.</last_name>
    <phone>+49-731-177</phone>
    <phone_ext>1200</phone_ext>
    <email>albert.ludolph@rku.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Neurology, University of Ulm</name>
      <address>
        <city>Ulm</city>
        <state>Baden-Württemberg</state>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albert C Ludolph, MD, Prof.</last_name>
      <phone>+49-731-177-</phone>
      <phone_ext>1200</phone_ext>
      <email>albert.ludolph@rku.de</email>
    </contact>
    <investigator>
      <last_name>Albert C Ludolph, MD, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Technische Universität München</name>
      <address>
        <city>Muenchen</city>
        <state>Bayern</state>
        <zip>D-81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Winkler, Prof. Dr.</last_name>
      <phone>+49 89 - 4140</phone>
      <phone_ext>4630</phone_ext>
      <email>drawinkler@yahoo.com.au</email>
    </contact>
    <investigator>
      <last_name>Andrea Winkler, Dr. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Universty of Regensburg</name>
      <address>
        <city>Regensburg</city>
        <state>Bayern</state>
        <zip>D-93053</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wilhelm Schulte-Mattler, Prof. Dr.</last_name>
      <phone>+49-941-941</phone>
      <phone_ext>0</phone_ext>
      <email>wilhelm.schulte-mattler@klinik.uni-regensburg.de</email>
    </contact>
    <investigator>
      <last_name>Wilhelm Schulte-Mattler, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, University of Wuerzburg</name>
      <address>
        <city>Wuerzburg</city>
        <state>Bayern</state>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Klebe Stephan, PD Dr.</last_name>
      <phone>+49-931-201-</phone>
      <phone_ext>5750</phone_ext>
      <email>Klebe_S@klinik.uni-wuerzburg.de</email>
    </contact>
    <investigator>
      <last_name>Stephan Klebe, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Deutsche Klinik für Diagnostik</name>
      <address>
        <city>Wiesbaden</city>
        <state>Hessen</state>
        <zip>D-65191</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bertold Schrank, Dr.</last_name>
      <phone>+49-611-577</phone>
      <phone_ext>431</phone_ext>
      <email>schrank.neuro@dkd-wiesbaden.de</email>
    </contact>
    <investigator>
      <last_name>Bertold Schrank, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, University of Rostock</name>
      <address>
        <city>Rostock</city>
        <state>Mecklenburg-Vorpommern</state>
        <zip>D-18147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johannes Prudlo, PD Dr.</last_name>
      <phone>+49-381-494</phone>
      <phone_ext>4742</phone_ext>
      <email>johannes.prudlo@med.uni-rostock.de</email>
    </contact>
    <investigator>
      <last_name>Johannes Prudlo, PD Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, University of Goettingen</name>
      <address>
        <city>Goettingen</city>
        <state>Niedersachsen</state>
        <zip>D-37073</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bettina Göricke, Dr.</last_name>
      <phone>+49-551-39</phone>
      <phone_ext>12581</phone_ext>
      <email>jochen.weishaupt@medizin.uni.goettingen.de</email>
    </contact>
    <investigator>
      <last_name>Bettina Göricke, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Medical School Hannover</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susanne Petri, Prof. Dr.</last_name>
      <phone>+49-511-532-</phone>
      <phone_ext>3740</phone_ext>
      <email>Petri.Susanne@mh-hannover.de</email>
    </contact>
    <investigator>
      <last_name>Susanne Petri, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neurologische Universitätsklinik Bergmannsheil</name>
      <address>
        <city>Bochum</city>
        <state>Nordrhein-Westfalen</state>
        <zip>44789</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Torsten Grehl, MD</last_name>
      <phone>+49-234-302-</phone>
      <phone_ext>6812</phone_ext>
      <email>Torsten.Grehl@rub.de</email>
    </contact>
    <investigator>
      <last_name>Torsten Grehl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Universty of Muenster</name>
      <address>
        <city>Muenster</city>
        <state>Nordrhein-Westfalen</state>
        <zip>D-48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Böntert, Dr.</last_name>
      <phone>+49-251-83</phone>
      <phone_ext>47955</phone_ext>
      <email>young@uni-muenster.de</email>
    </contact>
    <investigator>
      <last_name>Matthias Böntert, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Universty of Bonn</name>
      <address>
        <city>Bonn</city>
        <state>Nordrhrein-Westfalen</state>
        <zip>D-53105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael T. Heneka, Prof. Dr.</last_name>
      <phone>+49-228-287</phone>
      <phone_ext>13092</phone_ext>
      <email>michael.heneka@ukb.uni-bonn.de</email>
    </contact>
    <investigator>
      <last_name>Michael T. Heneka, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, University of Halle-Wittenberg</name>
      <address>
        <city>Halle/Saale</city>
        <state>Sachsen-Anhalt</state>
        <zip>06097</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Hanisch, Dr.</last_name>
      <phone>+49-345-557-</phone>
      <phone_ext>3340</phone_ext>
      <email>frank.hanisch@medizin.uni-halle.de</email>
    </contact>
    <investigator>
      <last_name>Frank Hanisch, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, TU Dresden</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>D-01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Hermann, Dr.</last_name>
      <phone>+49-351-458</phone>
      <phone_ext>2532</phone_ext>
      <email>alexander.storch@neuro.med.tu-dresden.de</email>
    </contact>
    <investigator>
      <last_name>Andreas Hermann, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, University of Jena</name>
      <address>
        <city>Jena</city>
        <state>Thueringen</state>
        <zip>D-07747</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julian Grosskreutz, PD Dr.</last_name>
      <phone>+49-3641-932</phone>
      <phone_ext>3426</phone_ext>
      <email>julian.grosskreutz@med.uni-jena.de</email>
    </contact>
    <investigator>
      <last_name>Julian Grosskreutz, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Humboldt University</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Meyer, MD, Prof.</last_name>
      <phone>+49-30-450560-</phone>
      <phone_ext>032</phone_ext>
      <email>thomas.meyer@charite.de</email>
    </contact>
    <investigator>
      <last_name>Thomas Meyer, MD, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Waibel S, Reuter A, Malessa S, Blaugrund E, Ludolph AC. Rasagiline alone and in combination with riluzole prolongs survival in an ALS mouse model. J Neurol. 2004 Sep;251(9):1080-4.</citation>
    <PMID>15372249</PMID>
  </reference>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 20, 2013</lastchanged_date>
  <firstreceived_date>June 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Ulm</investigator_affiliation>
    <investigator_full_name>Albert Christian Ludolph, Prof.</investigator_full_name>
    <investigator_title>MD, Prof.</investigator_title>
  </responsible_party>
  <keyword>amyotrophic lateral sclerosis</keyword>
  <keyword>survival time</keyword>
  <keyword>ALS functioning Rating Scale</keyword>
  <keyword>quality of life</keyword>
  <keyword>survival</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rasagiline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
